These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

59 related articles for article (PubMed ID: 20413999)

  • 1. Cardiovascular effects of growth hormone in adult hemodialysis patients: results from a randomized controlled trial.
    Kober L; Rustom R; Wiedmann J; Kappelgaard AM; El Nahas M; Feldt-Rasmussen B
    Nephron Clin Pract; 2010; 115(3):c213-26. PubMed ID: 20413999
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Growth hormone treatment during hemodialysis in a randomized trial improves nutrition, quality of life, and cardiovascular risk.
    Feldt-Rasmussen B; Lange M; Sulowicz W; Gafter U; Lai KN; Wiedemann J; Christiansen JS; El Nahas M;
    J Am Soc Nephrol; 2007 Jul; 18(7):2161-71. PubMed ID: 17554147
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Low total plasma homocysteine level in relation to malnutrition, inflammation, and outcome in hemodialysis patients.
    Akgul A; Bilgic A; Sezer S; Arat Z; Ozdemir FN; Haberal M
    J Ren Nutr; 2008 Jul; 18(4):338-46. PubMed ID: 18558298
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cardiovascular risk factors in hemodialysis and peritoneal dialysis patients.
    Helal I; Smaoui W; Hamida FB; Ouniss M; Aderrahim E; Hedri H; Elyounsi F; Maiz HB; Abdallah TB; Kheder A
    Saudi J Kidney Dis Transpl; 2010 Jan; 21(1):59-62. PubMed ID: 20061694
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Cardiovascular risk markers in hemodialysis].
    Urso S; Milone F; Garozzo M; Cannavò ME; Biondi A; Battaglia G
    G Ital Nefrol; 2004; 21 Suppl 30():S212-6. PubMed ID: 15750988
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mineral metabolism and cardiovascular morbidity and mortality risk: peritoneal dialysis patients compared with haemodialysis patients.
    Noordzij M; Korevaar JC; Bos WJ; Boeschoten EW; Dekker FW; Bossuyt PM; Krediet RT
    Nephrol Dial Transplant; 2006 Sep; 21(9):2513-20. PubMed ID: 16799173
    [TBL] [Abstract][Full Text] [Related]  

  • 7. OPPORTUNITY™: a large-scale randomized clinical trial of growth hormone in hemodialysis patients.
    Kopple JD; Cheung AK; Christiansen JS; Djurhuus CB; El Nahas M; Feldt-Rasmussen B; Mitch WE; Wanner C; Göthberg M; Ikizler TA
    Nephrol Dial Transplant; 2011 Dec; 26(12):4095-103. PubMed ID: 21750157
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inflammation, malnutrition, and cardiac disease as predictors of mortality in hemodialysis patients.
    Qureshi AR; Alvestrand A; Divino-Filho JC; Gutierrez A; Heimbürger O; Lindholm B; Bergström J
    J Am Soc Nephrol; 2002 Jan; 13 Suppl 1():S28-36. PubMed ID: 11792759
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The influence of growth hormone replacement on peripheral inflammatory and cardiovascular risk markers in adults with severe growth hormone deficiency.
    Deepak D; Daousi C; Javadpour M; Clark D; Perry Y; Pinkney J; Macfarlane IA
    Growth Horm IGF Res; 2010 Jun; 20(3):220-5. PubMed ID: 20185347
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Are metalloproteins and acute phase reactants associated with cardiovascular disease in end-stage renal failure?
    Healy H; Reith D; Morgan C; Clague A; Westhuyzen J
    Ann Clin Lab Sci; 2000 Jul; 30(3):295-304. PubMed ID: 10945571
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Homocysteine as a risk factor for cardiovascular disease in patients treated by dialysis: a meta-analysis.
    Heinz J; Kropf S; Luley C; Dierkes J
    Am J Kidney Dis; 2009 Sep; 54(3):478-89. PubMed ID: 19359080
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The redox state of albumin and serious cardiovascular incidence in hemodialysis patients.
    Terawaki H; Takada Y; Era S; Funakoshi Y; Nakayama K; Nakayama M; Ogura M; Ito S; Hosoya T
    Ther Apher Dial; 2010 Oct; 14(5):465-71. PubMed ID: 21175544
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Influence of growth hormone on whole body and regional soft tissue composition in adult patients on hemodialysis. A double-blind, randomized, placebo-controlled study.
    Hansen TB; Gram J; Jensen PB; Kristiansen JH; Ekelund B; Christiansen JS; Pedersen FB
    Clin Nephrol; 2000 Feb; 53(2):99-107. PubMed ID: 10711411
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Plasma sulfur amino acids in relation to cardiovascular disease, nutritional status, and diabetes mellitus in patients with chronic renal failure at start of dialysis therapy.
    Suliman ME; Stenvinkel P; Heimbürger O; Bàràny P; Lindholm B; Bergström J
    Am J Kidney Dis; 2002 Sep; 40(3):480-8. PubMed ID: 12200798
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association between serum albumin and mortality in dialysis patients is partly explained by inflammation, and not by malnutrition.
    de Mutsert R; Grootendorst DC; Indemans F; Boeschoten EW; Krediet RT; Dekker FW;
    J Ren Nutr; 2009 Mar; 19(2):127-35. PubMed ID: 19218039
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Observational study on markers of cardiovascular risk in renal patient: conventional hemodialysis vs. haemofiltration online.
    Melero-Rubio E; Párraga-Díaz M; Gómez-Sánchez MP; Pellicer-Villaescusa S; Merchán-Mayado E
    J Ren Care; 2009 Dec; 35(4):201-4. PubMed ID: 19909413
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Raised plasma total sialic acid levels are markers of cardiovascular disease in renal dialysis patients.
    Afzali B; Bakri RS; Bharma-Ariza P; Lumb PJ; Dalton N; Turner NC; Wierzbicki AS; Crook MA; Goldsmith DJ
    J Nephrol; 2003; 16(4):540-5. PubMed ID: 14696756
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Validity of plasma fibrinogen, D-dimer, and the von Willebrand factor as markers of cardiovascular morbidity in patients on chronic hemodialysis.
    Kirmizis D; Tsiandoulas A; Pangalou M; Koutoupa E; Rozi P; Protopappa M; Barboutis K
    Med Sci Monit; 2006 Feb; 12(2):CR55-62. PubMed ID: 16449948
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Plasma homocysteine levels and cardiovascular mortality in patients with end-stage renal disease.
    Buccianti G; Baragetti I; Bamonti F; Furiani S; Dorighet V; Patrosso C
    J Nephrol; 2004; 17(3):405-10. PubMed ID: 15365961
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessment of inflammatory factors and cardiac troponin T in hemodialysis patients.
    Falaknazi K; Bagheri N; Taziki O
    Saudi J Kidney Dis Transpl; 2009 Mar; 20(2):219-22. PubMed ID: 19237807
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.